Quadrant Biosciences Recognized as CenterState CEO's Business of the Year

Members of Quadrant Biosciences accept CenterState CEO’s award.

Quadrant Biosciences receives CenterState CEO's 2021 Business of the Year award.

SYRACUSE, NEW YORK, UNITED STATES, April 30, 2021 /EINPresswire.com/ — Quadrant Biosciences Inc, a developer of novel molecular diagnostic tools, has been named Business of the Year by CenterState CEO. The announcement was made during Centerstate CEO’s annual meeting this week, and recognized Quadrant for its outstanding work in diagnostics and surveillance tools to aid in the detection of COVID-19 in individuals and communities this past year. The Clarifi COVID-19 saliva test, developed by Quadrant in partnership with SUNY Upstate Medical University, has been administered well over a million times and is currently ranked as the most sensitive saliva test on the market by the FDA.

CenterState CEO, a business leadership organization based in New York, recognizes businesses in the region annually in five categories. Quadrant Biosciences won in the category "Business of the Year with more than 50 employees." Last year, the company was recognized by Centerstate CEO for Innovation Excellence.

"We're excited and honored to be recognized as the Business of the Year by Centerstate CEO," said Quadrant CEO and Founder Rich Uhlig. "From the start of the pandemic, our company was in a unique position to develop a diagnostic that could make an impact on our community. The Clarifi COVID-19 saliva test was the product of our great partnership with SUNY Upstate, as well as the tireless efforts of every member of our Quadrant team.”

—————————————-
About Quadrant Biosciences
Quadrant Biosciences is a life science company developing molecular diagnostic solutions for large-scale health issues. The company has entered into collaborative research relationships with a number of institutions including SUNY Upstate Medical University and Penn State University to explore and develop novel biomarker technologies with a focus on Autism Spectrum Disorder, concussion, and Parkinson's disease. Recently, it has leveraged its expertise in RNA analysis to co-develop a COVID-19 saliva test with SUNY Upstate Medical University. pandemic. Quadrant participates in the Start-up NY program, a New York State economic development program. For more information about Quadrant, please visit www.quadrantbiosciences.com.

David MacLean
Quadrant Biosciences Inc
+1 315-614-2325
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Pediatric Cancer Research Foundation joins Oncoheroes Biosciences on their unique approach to defeat childhood cancer

BOSTON, MASSACHUSETTS, UNITED STATES, April 30, 2021 /EINPresswire.com/ — For close to 40 years, Pediatric Cancer Research Foundation has been pioneering the effort to eliminate childhood cancer by identifying and funding promising leading edge research. Today, Oncoheroes Biosciences is thrilled to announce the investment of PCRF, the first time PCRF supports a biotech company.

Driven by the vision that every child deserves to grow up cancer free, PCRF exclusively targets its resources toward emerging and breakthrough research opportunities that demonstrate the best hope of a cure. “This year we are joining forces with Oncoheroes in their vision to collaborate with like-minded organizations to bring these new treatments to children with cancer. We’re stronger together.“ stated Jeri Wilson Executive Director of the Pediatric Cancer Research Foundation.

Every three minutes a family is diagnosed with childhood cancer and unfortunately, one in five will lose the battle. The lack of treatments designed and developed for children with cancer is unacceptable, with only 5 drugs specifically designed to treat children versus more than 200 for adults.

Developing new drugs is hard enough for therapies treating common diseases. The barriers only get higher for those with rare indications, like childhood cancer where foundations have been denouncing the lack of early-stage funding from the private sector; of incentives, and of industry interest.

“After years in the non-profit side of childhood cancer, I realized that investing resources only in academic research will not lead to new childhood cancer treatments, because research is only one piece of a complex jigsaw. Thus, we decided to launch Oncoheroes Biosciences, a mission-driven biotech company building a multi-asset pipeline exclusively focused on pediatric oncology. Thank you Pediatric Cancer Research Foundation for your vision and for going beyond your traditional research grant model. We will conquer childhood cancer if, together, we try something different.” explained Cesare Spadoni, co-founder and COO of Oncoheroes Biosciences.

Berta Marti Fuster
Oncoheroes Biosciences Inc
bmartifuster@oncoheroes.com
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Agilent Technologies Announces New Global Cannabis and Hemp Potency Testing Channel Partner, Ionization Labs

Agilent Technologies Logo

Ionization Labs presents Cann-ID SaaS Solution

Ionization Labs Cann-ID solution

Ionization Labs Cann-ID solution

New relationship enables accurate, rapid, scalable cannabis and hemp testing for customers around the world

Ionization Lab's Cann-ID solution is forward-thinking and addresses the needs that are beneficial to farmers, processors, and regulators.”

— Geoff Whaling, Chair of the National Hemp Association

AUSTIN, TX, UNITED STATES, April 30, 2021 /EINPresswire.com/ — Ionization Labs has joined Agilent Technologies as a Global Channel Partner to collaborate on sales, marketing, and ongoing product development of Ionization Labs' proprietary Cann-ID platform. Through this partnership, Ionization Labs will accelerate their reach, from 20 US states and three countries at present, to all 50 US states and all other countries with legal cannabis and or hemp industries included in Agilent's 100 plus country international sales distribution system.

The Cann-ID solution is an in-house cannabinoid testing solution for hemp and legal cannabis featuring cloud-based chemical data analytics software combined with an Agilent HPLC hardware platform. The platform supports the hemp and legal cannabis industries ecosystem, including extractors, cultivators, and processors tasked with improving extraction yield, process efficiency, and product compliance concerning cannabinoid derivatives. Cann-ID also supports the industries from regulatory and compliance, with Cann-ID's standardized cloud-based data platform that can support inter-state, intra-state, international import, and export. This tool even supports banking and insurance utilization as a risk mitigation tool. This is timely with the US Congress pushing the Safe Banking Act.

Industry leaders have recognized Cann-ID as a viable industry support solution. "As America's newest commodity crop, hemp provides so much potential for the new green economy. To reach its potential in the food and dietary supplement sectors, testing and standards will have to be vigorously developed", said Geoff Whaling, Chair of the National Hemp Association. "Ionization Lab's Cann-ID solution is forward-thinking and addresses the needs that are beneficial to farmers, processors, and regulators."

The Cann-ID solution Ionization Labs has developed an affordable, innovative potency testing solution, facilitating quick implementation and a strong return on investment relating to Cap-X and time. The solution was developed in an ISO-17025 analytical lab, utilizing proven and approved methods audited by A2LA. As such, not only are industry operators able to use Cann-ID in their four walls, it can also be deployed in professional analytical labs for COA (certification of analysis) purposes.

Co-Founder and President Cree Crawford shares, "Cann-ID brings a level of standardization and access to quality chemical data and analysis never before available. The ability for a processor or cultivator to have the same platform in their operations as the lab they are sending samples for COA approvals is a powerful and disruptive game-changer for industries in great need of standardization."

Cann-ID is available as a subscription SaaS model, which provides everything needed to run tests, including the Agilent HPLC hardware platform, Ionization Labs Cann-ID software, and consumables. Maintenance and technical support, including analytical chemists, are also available, giving clients access to a specialized support team ready to optimize their in-house testing needs.

For those seeking lab-grade, in-field chemical data, the Ionization Labs and Agilent partnership could not come at a better time, as the hemp and cannabis spaces continue to develop at a fever pitch and producers seek to out-perform competitors with higher quality and innovative new products. Cann-ID is a boon to organizations looking to maximize their data's value at unprecedented speeds and bring products to market.

"We are heavily focused on the next generation of domestic and international cannabis and hemp companies who are currently or are preparing to participate in interstate and international commerce, where chain-of-custody and independent trust verification systems are mission-critical to the success of their organizations," Alex Andrawes, Co-founder and CEO of Ionization Labs, says. "We see Agilent as a critical partner in the pathway to successful domestic and international cannabis and hemp commerce."

# # #
About Agilent Technologies
Agilent is a leader in life sciences, diagnostics, and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications, and expertise, enabling customers to gain the insights they seek. Agilent's expertise and trusted collaboration give them the highest confidence in our solutions.

About Ionization Labs
About Ionization Labs: Ionization Labs is an Austin, Texas-based SaaS chemical data platform company composed of agriculture, tech, CPG, and life sciences industry veterans. The company is committed to delivering robust chemical data solutions through standardization, innovation, and software to empower its clients with faster, higher-quality chemical data. The Ionization Labs' platform is considered to be the standard for next-generation chemical data solutions. For more information on Ionization Labs products and solutions, visit them online at www.ionizationslabs.com or on LinkedIn @Ionizations Labs.

Cree Crawford
Ionization Labs
media@ionizationlabs.com
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Research Antibodies and Reagents Market Growth Continues With Increasing Investment In Medical R&D

Research Antibodies And Reagents Market Report 2021: COVID-19 Growth And Change To 2030

Research Antibodies And Reagents Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Research Antibodies And Reagents Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON , UK, April 30, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Increasing investment in medical and health research and development (R&D) is predicted to contribute to the growth of the research reagent market and research antibodies market. In the field of life science research, antibodies and reagents are essential components for the investigation of biological processes or causes of diseases through careful experimentation, observation, laboratory work, analysis, and testing. According to the American Association for the Advancement of Science’s (AAAS) statistics published in December 2019, the total investment in medical and health research in the US grew by 6.4%. The health industry invested $129.5 billion (66.7%), followed by federal agencies investments of $43 billion (22.2%), and $21.7 billion (11.2%) invested by foundations, state & local governments, academic research institutions, and voluntary health associations. Thus, increasing investment in healthcare research and development will increase the utilization of research antibodies and reagents.

However, the global research antibodies and reagents market is expected to decline from $11.79 billion in 2020 to $11.57 billion in 2021 at a compound annual growth rate (CAGR) of -1.9%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The research antibodies and reagents market is expected to then reach $14.59 billion in 2025 at a CAGR of 6%.

Read More On The Global Research Antibodies and Reagents Market Report:
https://www.thebusinessresearchcompany.com/report/research-antibodies-and-reagents-global-market-report-2020-30-covid-19-growth-and-change

The research antibody diagnostic reagents market consists of sales of research antibodies, reagents and related services by entities (organizations, sole traders and partnerships) that produce research antibodies and reagents to diagnose and treat different diseases. The revenue generated by the market includes the sales of research antibodies in the form of primary and secondary antibodies extracted from sources such as mouse, rabbit and others, and reagents like stains & dyes, media & serum, fixatives, buffers, probe, solvents, enzymes and others. The companies involved in the research antibodies and reagents market are primarily engaged in developing antibodies and reagents for the application of proteomics, genomics, drug discovery and development by the pharmaceutical & biotechnology industries, academic & research institutes and contract research organizations.

The research antibodies and reagents market covered in this market is segmented by technology into western blot, immunofluorescence, immunohistochemistry, flow cytometry, enzyme-linked immunosorbent assay (ELISA), multiplex immunosorbent assay, immunoprecipitation, others; by application into proteomics, drug discovery & development, genomics; by end-user into pharmaceutical & biotechnology industry, academic & research institutes, contract research organizations (CROS).

Major players in the research reagent and antibody industry are Becton Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., F. Hoffmann La-Roche Ltd, Merck KGaA, PerkinElmer Inc., Lonza Group AG, Abcam plc, GenScript Biotech Corporation, and Bio-Techne Corporation.

Research Antibodies And Reagents Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides research antibodies and reagents market overview, forecast research antibodies and reagents market size and growth for the whole market, research antibodies and reagents market segments, and geographies, research antibodies and reagents market trends, research antibodies and reagents market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Research Antibodies and Reagents Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3418&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Scientific Research And Development Services Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/scientific-research-and-development-services-global-market-report-2020-30-covid-19-impact-and-recovery

Animal Testing And Non-Animal Alternative Testing Market – By Type (Animal Type, Industrial Application), Drivers, Restraints, Global Opportunities And Strategies – Global Forecast To 2035
https://www.thebusinessresearchcompany.com/report/animal-testing-and-non-animal-alternative-testing-market

Global Biologics Market – By Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), By Route Of Administration (Oral, Others (IV or IP)), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription Drugs, OTC Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2023
https://www.thebusinessresearchcompany.com/report/biologics-market

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Anatomic Pathology Equipment And Consumables Market Trends Include Investment In New Technologies For Efficiency

Anatomic Pathology Equipment And Consumables Market Report 2021: COVID-19 Growth And Change To 2030

Anatomic Pathology Equipment And Consumables Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Anatomic Pathology Equipment and Consumables Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 30, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Companies in the anatomic pathology equipment and consumables market are increasingly investing in new technologies for better efficiency and reducing the time taken to conduct these tests. Companies such as Biogenex have developed automated staining technology such as Xmatrx and i6000 diagnostics for diverse laboratory needs. Xmatrx systems offer standardized processes from baking through final glass coverslip for staining and prevent cross-contamination and i6000 diagnostics is a high-throughput system for special staining of clinical samples in molecular pathology laboratories. The i6000 diagnostics possesses a staining capacity of 200 slides in 8 hours (60 slides in 3 hours).

In June 2019, PHC Holdings Corporation acquired the anatomical pathology business of Thermo Fisher Scientific Inc for $1.14 billion. The acquired anatomical pathology business is expected to work as a new self-governing business named Epredia that will proceed to work as a leading global provider of comprehensive solutions in the anatomical pathology field, including instruments, consumables, and microscope slides.

Read More On The Global Anatomic Pathology Equipment And Consumables Market Report:
https://www.thebusinessresearchcompany.com/report/anatomic-pathology-equipment-and-consumables-global-market-report-2020-30-covid-19-growth-and-change

The global anatomic pathology equipment and consumables market is expected to grow from $17.46 billion in 2020 to $18.95 billion in 2021 at a compound annual growth rate (CAGR) of 8.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The anatomic pathology market size is expected to reach $26.31 billion in 2025 at a CAGR of 9%.

Major players in the anatomical pathology equipment and consumables market are Epridea, F. Hoffmann-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, Sakura Finetek, Agilent Technologies, Danaher Corporation, Bio SB, BioGenex Laboratories, and Quest Diagnostics Incorporated.

The equipment and consumables for anatomic pathology testing market covered in this report is segmented by products & services into instruments, consumables, services; by application into disease diagnosis, cancer, other diseases, medical research; by end-use into hospital laboratories, clinical laboratories, others.

Anatomic Pathology Equipment and Consumables Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides anatomic pathology equipment and consumables market overview, forecast anatomic pathology equipment and consumables market size and growth for the whole market, anatomic pathology equipment and consumables market segments, and geographies, anatomic pathology equipment and consumables market trends, anatomic pathology equipment and consumables market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Anatomic Pathology Equipment And Consumables Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3410&type=smp

Here Is A List Of Similar Reports By The Business Research Company:
Pharma Microbiology Testing Kits Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/pharma-microbiology-testing-kits-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-market-global-report-2020-30-covid-19-growth-and-change

Telemedicine Services Market – By Technology (Real Time, Store and Forward), By Application (Telecardiology, Telepsychiatry, Teledermatalogy, Teleradiology, Telepathology, Other Telemedicine Services) And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/telemedicine-services-market

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

A Major Biosimilar Monoclonal Antibodies Market Driver Is The Prevalence Of Chronic Diseases

Biosimilar Monoclonal Antibodies Market Report 2021: COVID-19 Growth And Change To 2030

Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 30, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune disease, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. According to the American cancer society (ACS), in 2020, about 1.8 million new cancer cases are expected in the United States. Therefore, the prevalence of chronic diseases including cancer is expected to drive the biosimilar monoclonal antibodies market.

The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease. Biosimilar monoclonal antibodies are highly similar to actual monoclonal antibodies in terms of pharmaceutical quality, safety, and efficacy, and are used to boost immunity by identifying and neutralizing foreign bodies. The market consists of revenue generated by the biosimilar monoclonal antibodies companies by the sales of these products.

Read More On The Global Biosimilar Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change

The global biosimilar monoclonal antibodies market is expected to grow from $3.52 billion in 2020 to $4.33 billion in 2021 at a compound annual growth rate (CAGR) of 23%. The biosimilar antibodies market growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The MAbs biosimilars market size is expected to reach $10.92 billion in 2025 at a CAGR of 26%.

The biosimilar monoclonal antibodies market covered in this report is segmented by type into synthetic chemicals, biopharmaceuticals, others, by application into chronic & autoimmune diseases, oncology, others, and by compound into Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab.

Major players in the biosimilar monoclonal antibodies market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, and Intas Pharmaceuticals Limited.

Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides biosimilar MAbs market overview, forecast biosimilar MAbs market size and growth for the whole market, biosimilar MAbs market segments, and geographies, biosimilar MAbs market trends, biosimilar MAbs market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Biosimilar Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Monoclonal Antibodies (MAbs) Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-mabs-global-market-report

Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/conjugated-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change

Biosimilar Therapeutic Peptides Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptides-global-market-report-2020-30-covid-19-growth-and-change

Interested to know more about The Business Research Company?

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

The largest European robotics and space event is counting down the time until take off

University teams construct their own Martian robots and then compete in competitions similar to tasks performed by rovers on the surfaces of Mars and the Moon.

KIELCE, POLAND, April 30, 2021 /EINPresswire.com/ — European Rover Challenge is an annual celebration of space enthusiasts. Starting in 2014, it is now the most important space-robotic event in Europe, bringing together hundreds of supporters and representatives of the world of science, technology, and business interested in developing innovative solutions in the field of mobile and space robotics. The event enjoys great popularity and prestige. The main event at ERC is the Martian robot competition, showcasing designs constructed by teams from around the world. This year's seventh edition gathered nearly 100 teams from 6 continents.

A shared passion for space technology, exploring the unknown, and taking humanity one step further, invariably gathers thousands of people around the world each year to watch contestants compete in their categories and put their ideas and solutions through many different tests.

This year’s ERC event will be held on September 10-12, 2021 in Poland. Almost 100 teams have registered to compete, including 58 teams who will take part in the ONSITE stationary mode and 38 teams who will compete hybrid in the REMOTE mode.

– As organisers of the ERC, we are really proud to see this community of young visionaries and their supporters getting bigger and bigger every year. The ultimate value of ERC lies in fostering and supporting this unique international ecosystem of knowledge sharing. We have been growing our community of young talents from technical universities around the world for 7 years in a row now, with every successive edition looking further and further beyond the horizon – says Lukasz Wilczyński from the European Space Foundation, the main organiser of the ERC.

Mapping Mars on Earth – Mars Yard
The competitions in which the teams constructing robots at the ERC participate, take place on a track called Mars Yard. Mars Yard is nothing less than a mapping of the conditions on the Red Planet, which the rovers have to deal with in numerous competitions. On the Mars Yard, built by planetary geologists and ERC experts, there are, therefore, craters, rock fragments, and hills. It's worth noting that the track is so accurately mapped that last year's track, in September 2020, replicated exactly where Perseverance has now landed. The spectacular visual effects are also complemented by the soil, which is due to the fact that Earth contains high levels of hematite, or iron oxide; on a level comparable to that on Mars.

New challenges and inspiration
With each new edition, the ERC organisers set the bar higher and higher for participants, as well as placing emphasis firmly on the educational aspect. Therefore, this year's edition will consist of two parts – the Competition Zone and the Inspiration Zone.

The Competition Zone is the venue for the eponymous event, the European Rover Challenge. This unique robotics competition goes beyond textbook theory, allowing students to design, build, and test the performance of autonomous rovers and then compete against other teams from around the world. The tasks prepared for the teams are based on real missions planned and executed by NASA or the European Space Agency, whose representatives are present at the ERC events as well as being based on real-life engineering experiences.

The Inspiration Zone will focus the attention of all those interested in scientific and technical demonstrations and presentations, both on-site and online. This part of the ERC is accompanied by a series of lectures and debates with keynote speakers coming from top international space and technology companies.

Special guests of previous editions of the ERC have included, among others Steve Jurczyk – current Acting Administrator of NASA, Harrison Schmitt – NASA astronaut and member of the legendary Apollo 17 mission, or Tim Peake – a British astronaut of the European Space Agency, who ran the London Marathon during his stay on the International Space Station.

Last year's sixth edition of ERC 2020 was held in a new hybrid format and was the only prestigious robotics and space tournament in the world to be held this year after the COVID-19 pandemic was declared worldwide. At the time, 30 teams from 14 countries took part, and their struggle was followed by over 100,000 people online.

Dominik Wartecki
ERC
+48 604705233
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

WIN's Digital Display Precision Predictor biomarker to guide cancer targeted therapy & predict response duration

WIN Consortium announces publication of the Digital Display Precision Predictor global biomarker prototype for cancer patients in NPJ Precision Oncology

VILLEJUIF, FRANCE, April 30, 2021 /EINPresswire.com/ —
The Worldwide Innovative Network in personalized cancer medicine consortium – WIN Consortium announces the publication of the Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival for cancer patients in NPJ Precision Oncology (10.1038/s41698-021-00171-6)

Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient’s tumor for all markers related to all possible targeted therapies becomes infeasible due to limited amount of tissue usually obtained by biopsies. In addition, the current companion diagnostic approach used for most targeted therapies provides limited treatment options, with a binary "yes/no" expected response to a drug and no recommendation for which treatment, among a range of possible options, is likely to be the best option for a particular patient.

The Digital Display Precision Predictor (DDPP), is a biomarker strategy and tool able to predict the duration of progression-free survival (PFS) for multiple targeted treatments for patients with advanced/metastatic cancers, based on the comprehensive investigation of the whole transcriptome (the gene expression profile of the tumor compared to that of normal tissue).
DDPP is based on: 1) the exploration of the whole transcriptome (20,000 genes) providing insight about the status of activation of almost all drug targets in the context of the network of genes or pathways that drive tumor progression; 2) the data can be obtained from a single assessment requiring very small amounts of tumor and analogous normal tissues; and 3) the prediction of the duration of the time until tumor progression (PFS) under a specific therapeutic regimen.

"One of the main challenges of finding new biomarkers is that they are built in a relatively small number of patients treated with the same drug (from the WINTHER trial), for whom both molecular profiles (from tumor and analogous normal tissues) and PFS data were available," said Dr. Josep Tabernero, Vice-Chairman and Chairman of Scientific Advisory Board of WIN, Director, Vall d'Hebron Institute of Oncology, VHIO (Spain) and past ESMO President (2018-2019).

"The DDPP is potentially a new global biomarker tool that can apply to any type of cancer drug used alone or in combination, agnostic of tumor type, and can lead, pending further prospective validation, to a new approach to optimal treatment selection for patients with cancer," concluded Dr. Richard L. Schilsky, Chairman of WIN.

__________________________________________________________________________________
About WIN Consortium
WIN Consortium is a non-profit association headquartered in France. The WIN network assembles 35 world-class academic medical centers, industries (pharmaceutical and diagnostic companies), research organizations and patient advocates spanning 19 countries and 4 continents, aligned to launch trials using its genomics and transcriptomics biomarker platform to bolster Precision Oncology across the world. WIN is the organizer of the WIN symposia in Precision Oncology.

Vladimir Lazar, MD, PhD
Worldwide Innovative Network WIN Consortium
+33 6 61 09 15 22
vladimir.lazar@winconsortium.org
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Thomas McMurrain, Digital Currency Bankless Banking Expert, Founder & CEO of CMDX, Inc, Zoom Interviewed DotCom Magazine

Thomas McMurrain, Digital Currency and Bankless Banking Expert, Founder & CEO of CMDX, Inc Agency Zoom Interviewed

Thomas McMurrain, Digital Currency and Bankless Banking Expert, Founder & CEO of CMDX, Inc Agency Zoom Interviewed

The DotCom Magazine Entrepreneur Spotlight Show

The DotCom Magazine Entrepreneur Spotlight Show

The DotCom Magazine Exclusive Zoom Interview

The DotCom Magazine Exclusive Zoom Interview

The DotCom Magazine Exclusive Entrepreneur Spotlight Series

The DotCom Magazine Exclusive Entrepreneur Spotlight Series

The DotCom Magazine Entrepreneur Spotlight Series

The DotCom Magazine Entrepreneur Spotlight Series

Thomas McMurrain, Digital Currency and Bankless Banking Expert, Founder and CEO of CMDX, Inc, Zoom Interviewed for The DotCom Magazine

Having a leading voice in the Digital Currency space was a true honor. Thomas McMurrain is a visionary entrepreneur.”

— Andy "Jake" Jacob, CEO, DotCom Magazine

SAN FRANCISCO, CALIFORNIA, UNITED STATES, April 29, 2021 /EINPresswire.com/ — Thomas McMurrain, Outstanding Digital Currency and Bankless Banking Expert, and Founder and CEO of CMDX, Inc, Zoom Interviewed for The DotCom Magazine Entrepreneur Spotlight Series.

Thomas McMurrain, prominent Digital Currency and Bankless Banking expert, and Founder and CEO of CMDX, Inc joins other leaders, trailblazers, and thought leaders being Interviewed for the popular DotCom Magazine Entrepreneur Spotlight Series.

Thomas McMurrain has been Zoom Interviewed by Andy “Jake” Jacob, CEO of DotCom Magazine for the Online Magazine’s Entrepreneur Spotlight Video Interview Series. Thomas McMurrain joins other leaders selected by the editorial team of DotCom Magazine be interviewed on compelling video series.

FOR IMMEDIATE RELEASE

Thomas McMurrain, a leading Digital Currency and Bankless Banking expert, and successful Founder and CEO of CMDX, Inc has been Zoom interviewed by DotCom Magazine as part of the online magazine’s Entrepreneur Spotlight Video Interview Series.

Thomas McMurrain of CMDX, Inc Agency joins other leading CEO’s, founders, and thought leaders that have participated in this informative and popular video interview series. In the interview, Thomas McMurrain discusses the newest offerings of CMDX, Inc Agency, what makes the company different than other firms, and shares unique thoughts on leadership and entrepreneurship. Thomas McMurrain joins other leaders building strong and compelling companies that have been invited to participate in the exclusive video series.

Andy Jacob, CEO of DotCom Magazine says, “The interview with Thomas McMurrain was wonderful. He has an excellent background in the Digital Currency and Bankless Banking space. The success of CMDX, Inc is a true testament to their team and their people. It was a real honor to have Thomas McMurrain on the video series. Interviewing Thomas McMurrain was a lot of fun, educational and quite interesting. It was awesome to have Thomas McMurrain on the show, and I know people will be absolutely intrigued by what he has to say.”

Andy Jacob continues, “It is the goal of DotCom Magazine to provide the absolute best in what entrepreneurship has to offer. We have interviewed many of the leading entrepreneurs in their respective field, and Thomas McMurrain of CMDX, Inc has a remarkably interesting story. We were incredibly happy to have Thomas McMurrain on the show as it takes amazing leadership to build a company like CMDX, Inc. There are so many powerful and talented entrepreneurs throughout the world. I am extremely fortunate to interview the best of the best, and I always come away humbled by how many brilliant and talented people are building amazing companies. Thomas McMurrain and CMDX, Inc are providing an out of the mark service to their clients, and they have leveraged their team’s background and experience to build a terrific company. As we scout the world for competent entrepreneurs and companies, it is always a wonderful experience for to meet leaders like Thomas McMurrain who are forging an incredible path for others. At DotCom Magazine, we believe entrepreneurs are the heartbeat of the world. We believe it is a world where risk takers must be lauded, saluted, and respected. Outstanding entrepreneurs know that nothing is given to them. Successful entrepreneurs get up every morning and give an amazing effort. We salute the leaders of this world like Thomas McMurrain”.

DotCom Magazine is a leading news platform providing fascinating interviews with news makers, thought leaders, and entrepreneurs. DotCom Magazine is the leader in putting people with insatiable entrepreneurial spirit at the forefront of every story it publishes. The Entrepreneur Spotlight Interview Video Series looks at business through the lens of a successful entrepreneur’s mindset. The Entrepreneur Spotlight Series has included many high-profile leaders, including Inc500 founders, Ted Talk presenters, ABC Shark Tank participants, venture backed visionaries, high profile CEO’s and Founders, and many other wonderful thought leaders and entrepreneurs. DotCom Magazine covers Founders and CEO’s making a difference. Regardless of who the entrepreneur is, where they live, or what they are doing, if it is interesting and newsworthy, DotCom Magazine covers it. In selecting entrepreneurs for this important video series, we consider the newsworthiness of the story and what our readers want to learn about. If something is important to our readers, it is important to DotCom Magazine. The people at DotCom Magazine believe in including a diverse range of entrepreneur voices in our reporting, actively pursuing diversity in our entrepreneurs, and listening to our readers and viewers to make sure we are as open and responsive as possible.

PRESS CONTACT: ANDY “JAKE” JACOB, EDITOR IN CHIEF, DOTCOM MAGAZINE
Email: Andy@DotComMagazine.com
Phone: 602-909-9890
Further Information: http://www.DotComMagazine.com

andrew jacob
DotCom Magazine
+1 602-909-9890
email us here

Thomas McMurrain, Digital Currency and Bankless Banking Expert, Founder & CEO of CMDX, Inc, Zoom Interviewed


Source: EIN Presswire

DermaCare BioSciences Starts GoFundMe Campaign to raise Money for Rapid COVID Antigen Tests for India

EasyRapidNOW Nasal Swab Antigen Test Kit – Help Stop the Spread!

Rapid Nasal Swab Antigen Tests for India – Help Control the Spread of COVID19

Research shows rapid antigen tests can work in a real world setting – with asymptomatic and symptomatic people.

USA Based DermaCare BioSciences, a div of Dermacare Packaging & Private Label launches a GoFundMe campaign to raise money for Rapid Antigen Test Kits for India.

India is in dire need of COVID supplies. Our rapid nasal swab antigen tests produce reliable results in minutes and will help by rapidly recognizing infected individuals.”

— Kelly Stone, Co-Founder Dermacare

DELRAY BEACH, FLORIDA, UNITED STATES, April 29, 2021 /EINPresswire.com/ — USA Based DermaCare BioSciences, a division of Dermacare Packaging & Private Label, LLC has started a GoFundMe campaign to raise money for Rapid Antigen Test Kits for India.

The company, based in South Florida, has had success supplying millions of these Covid-19 rapid tests worldwide for nearly a year, according to Chief Sales Officer and GoFundMe Organizer, Kelly Stone.

“India is in dire need of COVID supplies”, said Stone. “We’ve been producing and distributing Rapid Antigen Tests since 2020. These tests detect certain proteins in the virus using a non-invasive nasal swab to get a fluid sample. Our antigen tests can produce results in minutes and help India to get Covid under control by rapidly recognizing infected individuals.”

Stone goes on to say, “We want to raise money to donate 1 Million tests to start. We as a company are donating 10,000 tests. Please help us reach our goals so we can get at least 1 Million Tests to India ASAP and help stop the spread of COVID 19!”

For more information about this campaign to help India through rapid testing, please visit: https://gofundme.com/f/india-needs-rapid-cv19-tests

About Dermacare Biosciences.

DermaCare BioSciences, a division of Dermacare Packaging & Private Label, LLC is an R&D-focused biotechnology company that develops, manufactures, distributes and supplies high-quality rapid test kits for COVID-19 as well as other medical device and PPE products.
www.easyrapidcovidtestkits.com www.dermacareline.com www.dermacarebio.com

With offices in South Florida and Asia, they are a diversified company that also handles advertising & marketing solutions for healthcare, pharmaceutical, and Fortune 500 companies.

Contact: Kelly Stone, Chief Sales Officer, kelly@dermacarepkg.com; M: 954-465-6408

Rich Butler
Dermacare Packaging & Private Label, LLC
+1 561-818-9105
email us here
Visit us on social media:
LinkedIn

Easy RapidNOW Nasal Swab Antigen Test Kits from DermaCare


Source: EIN Presswire